GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Artgen Biotech PJSC (MIC:ABIO) » Definitions » Valuation Rank

Artgen Biotech PJSC (MIC:ABIO) Valuation Rank


View and export this data going back to 2006. Start your Free Trial

What is Artgen Biotech PJSC Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Artgen Biotech PJSC Valuation Rank Related Terms

Thank you for viewing the detailed overview of Artgen Biotech PJSC's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Artgen Biotech PJSC (MIC:ABIO) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Artgen Biotech PJSC (MIC:ABIO) » Definitions » Valuation Rank
Comparable Companies
MIC:LIFE OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX BGNE SZSE:300122 ALNY OCSE:GMAB XKRX:068270 BMRN XBRU:UCB RPRX LEGN
Traded in Other Exchanges
N/A
Address
Prospect of the 60th Anniversary, Moscow, RUS, 117036
Website
https://www.hsci.ru
Artgen Biotech PJSC formerly Human Stem Cells Institute PJSC is a biotechnology company. It is engaged in the drug discovery, research and development and marketing of proprietary products and services in the field of regenerative medicine, bio-insurance, medical genetics, including reproductive genetics, gene therapy, and biopharmaceutics. The company has developed Neovasculgen, which is a gene therapy drug for the treatment of Peripheral Arterial Disease, including Critical Limb Ischemia and also develops SPRS therapy which entails the use of autologous dermal fibroblasts to repair skin damage due to aging and other structural changes.